Antidote

Overview

US health-insurance company in timor-arbel-sadras’s portfolio (“we invested”), cited as the archetype of the existing-market-failure insurtech: large legacy health carriers — decades old, running disconnected, untouchable legacy systems — cannot handle their own data masses, making the market unprofitable and unmanageable. Antidote builds greenfield with AI-native tooling and identifies the ~2% of claims responsible for ~50% of costs in seconds, versus years for incumbent carriers.

Relationships

• timor-arbel-sadras — investor and source of everything on this page.

Notes

• Relevance to the team: the template for “AI-native entrant vs. old gorillas on legacy systems” — the same structural asymmetry the AI-brokerage thesis relies on, applied on the carrier side.
• (Company details beyond the meeting testimony unknown — needs source; name transliterated from Hebrew transcript.)

Mentioned in

• 2026-08-09-directions-timor-arbel-sadras-growth-vc-advisory — the existing-market-failure archetype example.